US 12,110,553 B2
Methods for diagnosing and assessing risk of developing glomerulosclerosis
Martin Pollak, Brookline, MA (US); Elizabeth J. Brown, Dallas, TX (US); and Johannes Schlondorff, Chestnut Hill, MA (US)
Assigned to The Brigham and Women's Hospital, Inc., Boston, MA (US); and Children's Medical Center Corporation, Boston, MA (US)
Filed by The Brigham and Women's Hospital, Inc., Boston, MA (US); and Children's Medical Center Corporation, Boston, MA (US)
Filed on Dec. 7, 2020, as Appl. No. 17/113,957.
Application 17/113,957 is a continuation of application No. 15/297,804, filed on Oct. 19, 2016, granted, now 10,858,705.
Application 15/297,804 is a continuation of application No. 13/513,447, granted, now 9,499,867, issued on Nov. 22, 2016, previously published as PCT/US2010/059316, filed on Dec. 7, 2010.
Claims priority of provisional application 61/267,313, filed on Dec. 7, 2009.
Prior Publication US 2021/0198740 A1, Jul. 1, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6811 (2018.01); C12Q 1/6813 (2018.01); C12Q 1/6816 (2018.01); C12Q 1/6827 (2018.01); C12Q 1/6876 (2018.01); C12Q 1/6883 (2018.01); G01N 33/68 (2006.01); C12Q 1/6886 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 1/68 (2013.01); C12Q 1/6811 (2013.01); C12Q 1/6813 (2013.01); C12Q 1/6816 (2013.01); C12Q 1/6827 (2013.01); C12Q 1/6876 (2013.01); G01N 33/6854 (2013.01); G01N 33/6893 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); G01N 2800/347 (2013.01)] 12 Claims
 
1. A method of preparing a sample from a subject suspected of having a risk for developing focal segmental glomerulosclerosis (FSGS), the method comprising enriching the sample for inverted formin 2 (INF2) nucleic acid molecules by contacting the sample with a detectably labeled oligonucleotide that specifically binds to an INF2 nucleic acid having the sequence of SEQ ID NO: 21 comprising a mutation in at least one nucleotide position corresponding to a position selected from the group consisting of 736, 795, 784, 699, 693, 796, 801, and 268 of SEQ ID NO: 21,
wherein the detectably labeled oligonucleotide comprises a sequence having at least 15 consecutive nucleotides of the sequence of the INF2 nucleic acid or a complementary sequence thereof, and
wherein the sequence of the detectably labeled oligonucleotide comprises the mutation.